The 2017 American Thoracic Society (ATS) International Conference was held in Washington, DC, May 19–24, 2017. As a leading meeting in respiratory medicine, dedicated to advancing the clinical and scientific understanding of pulmonary diseases, critical illnesses, and sleep-related breathing disorders, the ATS Conference attracts thousands of participants from around the world. The 2017 ATS conference featured 6700 original research projects, 500 sessions, and 800 speakers. In this activity, 2 experts summarize the key learnings on COPD from this year’s conference.
Elsevier's CME pulmonary activities are geared for pulmonologists, respiratory specialists, primary care physicians, and other healthcare clinicians responsible for the care of patients with respiratory issues.
Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary CareFormat: Webcast
This CME-accredited Through Your Patient’s EyesTM program is intended for primary care providers and other clinicians who manage patients with asthma. This educational activity has been designed to highlight issues faced by people living with asthma, including patients’ perspectives on the burdens of severe disease, difficulties related to suboptimal health literacy, and potential hurdles that can arise in busy healthcare practices. Specialist and primary care faculty discuss practical advice on overcoming these challenges, how to best coordinate multidisciplinary care, and actionable recommendations on identifying, comprehensively assessing, and longitudinally managing patients with severe asthma. As a result, clinician learners will be better prepared to engage and educate their patients with severe asthma, while improving long-term outcomes through personalized evidence-based care.
This CME-accredited Clinical Research UpdatesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the identification, evaluation, and treatment of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate the latest evidence for severe asthma phenotypes, the clinical utility of various disease biomarkers, and the profiles of current and emerging biologic therapies, with a focus on individualizing treatment plans. Faculty also incorporate the perspectives of patients with asthma, including the burdens of severe disease, hidden challenges to good long-term outcomes, and the benefits of shared decision-making.
Current Strategies for the Long-term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator TherapyFormat: Webcast
The content for this activity is based on the satellite symposium, “Current Strategies for the Long-term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator Therapy” that was presented at the 39th European Cystic Fibrosis Society Conference on June 10, 2016. The emergence of novel targeted agents, that directly correct CFTR loss function alleles, has created new treatment opportunities for patients with cystic fibrosis with advanced disease.
CHEST 2016: Understanding the Role of Targeted Biologic Therapies in the Treatment of Patients with Moderate-to-Severe, Persistent AsthmaFormat: Medical Meeting Reporter
This CME program will focus on information on the clinical decision-making for management of patients with asthma that were presented at the CHEST 2016 Annual Meeting from October 22 - 26, 2016 in Los Angeles, California. The expert faculty of this program will discuss conference highlights and provide a comprehensive analysis of clinical decision-making in patients with asthma. They will discuss the effectiveness of communicating therapeutic decisions with patients. This program will give physicians a better understanding of when to implement data-driven, patient-specific treatment plans to improve outcomes for patients with asthma.
Potentially practice-changing data from clinical trials in non-small cell lung cancer (NSCLC) were presented at the European Society for Medical Oncology (ESMO) 2016 Congress on October 7–11 in Copenhagen, Denmark. These data may not only lead to new treatment options but also help clinicians use existing treatment options more effectively. In this video presentation, two leading experts in the management of NSCLC review key results presented at ESMO 2016 and provide insights on how the results may influence practice today.
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and TreatmentFormat: Webcast
The content for this activity is based on the satellite symposium Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment that was presented on October 24, 2016 in Los Angeles, CA. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors.
Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic FibrosisFormat: Webcast
The content for this activity is based on the satellite symposium, “Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis”, that was presented at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida on October 28, 2016. The content highlights the latest advancements, particularly in CFTR-based therapeutics, for the treatment of patients with cystic fibrosis. Expert faculty discuss the most up-to-date analysis for clinical decision-making, including updates on assessment, monitoring, and management of patients treated with CFTR modulator therapies. The goal of this activity is to increase the knowledge and competencies of the multidisciplinary team involved in the management of patients with CF, and provide strategies for improving the lives of patients. Upon completion of this activity, healthcare providers will be better equipped with imperative information for creating more effective personalized treatment plans and improving patient outcomes.